Healthcare Private Placement and M&A Transactions Review Week Ending November 10, 2024

ZAP Surgical: The company raised $78 million of Series E venture funding in a deal led by Baheal Pharmaceutical Group on November 8, 2024. The company is an operator of a medical technology business intended to develop a next-generation radio surgical robot for non-invasive tumor ablation.

AmplifyBio: The company raised $50 million of venture funding from Vitrian on November 6, 2024. The company is an operator of a biotechnology platform intended to accelerate the development of therapies and vaccines.

Inquis Medical: The company raised $40 million of Series B venture funding in a deal led by Marshall Wace on November 4, 2024. ShangBay Capital, Yu Galaxy, En Pointe, Pierre Lamond and other undisclosed investors also participated in the round. The company is a developer of a peripheral thrombectomy medical device intended to address unmet clinical needs and improve the standard of care.

Sage: The company raised $35 million of venture funding from undisclosed investors on November 7, 2024. The company is a developer of elder assistance software designed to connect patients with their loved ones through voice when traditional phones and emergency response systems are out of reach.

PrognomIQ: The company raised $34.3 million of Series D venture funding in a deal led by Seer on November 5, 2024. Bruker, The Invus Group, aMoon Fund, Catalio Capital Management, and other undisclosed investors also participated in the round. The company is a developer of medical test products designed for the detection and treatment of cancer and other complex diseases.

OptraScan: The company raised $30 million of Series B venture funding in a deal led by Molbio Diagnostics on November 6, 2024, putting the company’s pre-money valuation at $19 million. The company is a provider of a pathology system designed to scan and analyze tissue.

Mach5 Therapeutics: The company raised $19.2 million of venture funding from undisclosed investors on November 4, 2024. The company is a developer of therapeutics intended for immune-mediated inflammatory and fibrotic diseases.

CrossBridge Bio: The company raised $10.8 million of venture funding in a deal led by Texas Medical Center and CE-Ventures on November 4, 2024. Crescent Enterprises, Alexandria Venture Investments, Linden Lake Venture Capital, and Portal Innovations and other undisclosed investors also participated in the round. The company is a developer of a biotechnology platform of antibody-drug conjugates (ADCs) intended for cancer treatment.

Synthesis Health: The company raised $9.5 million of venture funding from CME Ventures, Hilltop Venture Partners and Break Off Capital on November 4, 2024. Tribune Capital also participated in the round. The company is a developer of a health imaging platform designed to help healthcare specialists.

Adipo Therapeutics: The company closed on $8 million of an undisclosed targeted amount of venture funding on November 7, 2024. The company is a developer of polymer-based nanoparticles designed for the treatment of obesity-related diseases.

CoachCare: The company received $7 million of development capital from undisclosed investors on November 7, 2024. The company is a developer of a virtual health and remote patient monitoring platform designed to offer personalized programs for weight loss.

AllFocal Optics: The company raised $5.3 million of venture funding though a combination of grant and equity in a deal led by Speedinvest on November 6, 2024. 7percent Ventures, Martlet Capital, another.vc and Mario Götze also participated in the round. The company is a developer of a nanophotonic lens technology.

Augmental: The company raised $4 million of venture funding from Murata Manufacturing Company, SCI Ventures and Carao Ventures on November 5, 2024. Fen Ventures also participated in the round. The company is a developer of augmented reality technology designed to overcome the physical and sensory limitations of patients with paralysis.

EpiBone: The company raised an undisclosed amount of venture funding in the form of convertible debt in a deal led by Kendall Capital Partners on November 8, 2024. EMV Capital and LifeSpan Vision Ventures, and other undisclosed investors also participated in the round. The company is a developer of a skeletal bone reconstruction technology through three-dimensional design and living cells.

NVasc: The company raised an undisclosed amount of venture funding from Mitsui Global Investment in November 2024. The company is an operator of a biopharmaceutical business focused on treating blindness.

Avid Bioservices / Ampersand Capital Partners: The company has entered into a definitive agreement to be acquired by GHO Capital and Ampersand Capital Partners in an estimated $1.1 billion LBO on November 7, 2024 through a public-to-private transaction. Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell cultures.

Ambry Genetics / Tempus AI: The company reached a definitive agreement to be acquired by Tempus AI for $600 million on November 4, 2024. The company is an operator of a genetics diagnostics business intended to provide a comprehensive suite of genetic testing applications for inherited and non-inherited diseases.

Nektar Therapeutics / Ampersand Capital Partners: Ampersand Capital Partners reached a definitive agreement to acquire the reagent business division of Nektar Therapeutics through a $90 million LBO on November 4, 2024. The company engages in manufacturing and distributing reagent substances and therapeutics.

Cortex / Boston Scientific: The company reached a definitive agreement to be acquired by Boston Scientific for an undisclosed amount as of November 4, 2024. The company is an operator of a medical technology business intended to guide the treatment of atrial fibrillation.

inveox / Unknown Investor: The company was acquired for an undisclosed amount on November 7, 2024. The company is a developer of a database platform intended to digitize, automate, and connect pathology laboratories.

Kalaris Therapeutics / AlloVir: The company reached a definitive agreement to acquire AlloVir through a reverse merger, resulting in the combined entity trading on the NASDAQ under the ticker symbol KLRS. The company is an operator of a clinical-stage ophthalmology biotech business intended to help patients by addressing retinal disease therapies.

Kyber Data Science / Forian: The company was acquired by Forian for an undisclosed amount on November 6, 2024. The company is a provider of an investment data analytics platform intended for insights into the healthcare market.

Lomond Therapeutics / Venetian-1 Acquisition Corp: The company acquired Venetian-1 Acquisition Corp through a reverse merger on November 04, 2024. The company is a developer of a biopharmaceutical platform designed to target escape mutations in hematological cancers.

Optimum Processing / Savillex: The company was acquired by Savillex, via its financial sponsor Thompson Street Capital Partners, through an LBO on November 7, 2024 for an undisclosed amount. The company is a manufacturer of innovative, single-use bioprocessing bags and systems..

Radar Healthcare / Marlin Equity Partners: The company was acquired by Marlin Equity Partners through an LBO on November 8, 2024 for an undisclosed amount. The company is a developer of healthcare software designed to improve safety, performance, and quality of care.

Renexxion / Relief Therapeutics: The company is in talks with Relief Therapeutics through a reverse merger for an undisclosed amount as of November 11, 2024. The company is a developer of naronapride drugs designed to treat gastrointestinal disorders.

SensID / Microbiologics: The company was acquired by Microbiologics, via its financial sponsor Granite Partners, through an LBO on November 6, 2024 for an undisclosed amount. The company is a manufacturer of biotechnology reference materials and quality controls designed for molecular diagnostics with a focus on oncology and precision medicine.